The experience with colorectal cancer screening in the Czech Republic: the detection at earlier stages and improved clinical outcomes.


Journal

Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 10 02 2020
revised: 11 05 2020
accepted: 12 05 2020
pubmed: 8 7 2020
medline: 21 10 2020
entrez: 8 7 2020
Statut: ppublish

Résumé

Colorectal cancer (CRC) remains a major health burden. Although screening is recommended and considered beneficial, further data on its positive effects are needed for worldwide implementation. The aim of our national multicentre prospective observational study was to reveal and document clinicopathological differences in CRC diagnosed by screening and presented by disease symptoms as well as assess the efficiency of the screening programme in the Czech Republic. Between March 2013 and September 2015, a total of 265 patients were enrolled in 12 gastroenterology centres across the Czech Republic. Patients were divided into screening and symptomatic groups and compared for pathology status and clinical characteristics. Screening was defined as a primary screening colonoscopy or a colonoscopy after a positive faecal occult blood test in an average-risk population. The distribution of CRC stages was significantly (statistically and clinically) favourable in the screening group (predominance of stages 0, I and II) compared with the non-screening group (P < 0.001). The presence of distant and local metastases was significantly less frequent in the screening group than in the symptomatic group (P < 0.001). Patients in the screening group had a higher probability of radical surgery (R0) than those diagnosed based on symptoms (P < 0.001). Systemic palliative treatment was indicated in two patients in the screening group compared with 23 patients in the non-screening group (P = 0.018). CRC diagnosed by screening disclosed less advanced clinicopathological characteristics and results in patients with a higher probability of radical surgery (R0) than diagnoses established based on symptoms, with subsequent management differing accordingly between both groups. These results advocate the implementation of a suitable worldwide screening programme.

Identifiants

pubmed: 32634606
pii: S0033-3506(20)30183-9
doi: 10.1016/j.puhe.2020.05.021
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

153-158

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

J Kral (J)

Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology, Prague, Czech Republic; Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic. Electronic address: jan.kral@centrum.cz.

V Kojecky (V)

T. Bata Hospital, Gastroenterology Department, Zlin, Czech Republic.

M Stepan (M)

Vitkovice Hospital, Gastroenterology Department, Vitkovice, Czech Republic.

M Vladarova (M)

Brno University Hospital, Gastroenterology Department, Brno, Czech Republic.

O Zela (O)

Frydek-Mistek Hospital, Gastroenterology Department, Frydek-Mistek, Czech Republic.

J Knot (J)

Klaudian Hospital, Gastroenterology Department, Mlada Boleslav, Czech Republic.

M Jakovljevic (M)

Gastroenterology Private Practice, Hluboka Nad Vltavou, Czech Republic.

Z Kralova (Z)

Medic Kral, Ltd., Gastroenterology Private Practice, Prague, Czech Republic.

R Buresova (R)

Chomutov Hospital, Gastroenterology Department, Chomutov, Czech Republic.

T Grega (T)

Military University Hospital, Gastroenterology Department, Prague, Czech Republic.

D Bauman (D)

Masaryk Hospital, Gastroenterology Department, Rakovnik, Czech Republic.

J Kotyza (J)

University Hospital Plzen, Gastroenterology Department, Plzen, Czech Republic.

R Stepanova (R)

International Clinical Research Centre of St. Anne's University Hospital, Brno, Czech Republic.

T Hucl (T)

Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology, Prague, Czech Republic.

P Vodicka (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic; Faculty of Medicine and Biomedical Center in Pilsen, Pilsen and First Medical Faculty, Prague, Charles University, Czech Republic.

L Vodickova (L)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic; Faculty of Medicine and Biomedical Center in Pilsen, Pilsen and First Medical Faculty, Prague, Charles University, Czech Republic. Electronic address: ludmila.vodickova@iem.cas.cz.

J Spicak (J)

Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH